How can digital reporting benefit a pharmaceutical company during inspections? Response:

Question

Options

• ABy allowing real-time updates and transparency.
• BBy eliminating the need for any future inspections.
• CBy automatically marketing products during the inspection.
• DBy reducing the need for employee training.

• A
  78% (14)
• B
  11% (2)
• C
  6% (1)
• D
  6% (1)

Explanation

Digital reporting enables pharmaceutical companies to provide inspectors with immediate, accurate, and traceable data - real-time updates mean discrepancies can be flagged and corrected on the spot, while transparency builds trust with regulatory bodies like the FDA or EMA. Option B is wrong because digital reporting improves inspections, not eliminates them - regulators will always require oversight of pharmaceutical operations. Option C confuses a compliance tool with a marketing function; inspections focus on safety and regulatory adherence, not product promotion. Option D is incorrect because robust reporting systems actually require trained employees to operate, interpret, and maintain them correctly.

Memory tip: Think of digital reporting as a "live dashboard" for inspectors - just like a hospital monitor shows patient vitals in real time, digital reporting shows compliance status in real time. If the answer mentions something inspectors could see and act on immediately, that's your signal for option A.

No community discussion yet for this question.